Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by University of Washington.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University of Washington
ClinicalTrials.gov Identifier:
NCT00362297
First received: August 8, 2006
Last updated: April 29, 2011
Last verified: April 2011

August 8, 2006
April 29, 2011
September 2006
September 2011   (final data collection date for primary outcome measure)
Frequency of HSV-2 total shedding from the genital tract as measured by PCR, calculated using a per-day shedding rate in participants treated with high-dose acyclovir as compared to once-daily valacyclovir. [ Time Frame: 15 weeks ] [ Designated as safety issue: No ]
Frequency of HSV-2 total shedding from the genital tract as measured by PCR, calculated using a per-day shedding rate in participants treated with high-dose acyclovir as compared to once-daily valacyclovir.
Complete list of historical versions of study NCT00362297 on ClinicalTrials.gov Archive Site
  • Frequency of subclinical shedding from the genital tract as measured by PCR, calculated using a per-day shedding rate in participants treated with high-dose acyclovir as compared to once-daily valacyclovir. [ Time Frame: 15 weeks ] [ Designated as safety issue: No ]
  • Frequency of lesional shedding from the genital tract as measured by PCR, calculated using a per day shedding rate in participants treated with high-dose acyclovir as compared to once-daily valacyclovir. [ Time Frame: 15 weeks ] [ Designated as safety issue: No ]
  • Number of herpes recurrences, defined clinically as >=1 successive day on which genital lesions are present, in participants treated with high-dose acyclovir as compared to once-daily valacyclovir. [ Time Frame: 15 weeks ] [ Designated as safety issue: No ]
  • Frequency of subclinical shedding from the genital tract as measured by PCR, calculated using a per-day shedding rate in participants treated with high-dose acyclovir as compared to once-daily valacyclovir.
  • Frequency of lesional shedding from the genital tract as measured by PCR, calculated using a per day shedding rate in participants treated with high-dose acyclovir as compared to once-daily valacyclovir.
  • Number of herpes recurrences, defined clinically as >=1 successive day on which genital lesions are present, in participants treated with high-dose acyclovir as compared to once-daily valacyclovir.
Not Provided
Not Provided
 
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults

The purpose of the research study is to evaluate the effectiveness of high-dose acyclovir compared to valacyclovir for reduction of asymptomatic genital shedding in persons with genital herpes.

The study will enroll men and women who are 18 years or older, test positive to HSV-2 (by blood test) and have had a first outbreak of HSV-2 within the past 6 months or have had at least 4 genital herpes outbreaks in the past year. Participants must be HIV negative and willing to stop taking suppressive therapy for HSV for the one week wash out period. (Females only: You must not be pregnant or breast-feeding). Both men and women will be asked to use an effective form of birth control.

Involvement in the study will last 15-weeks and you will be asked to visit the clinic every 2-weeks. At each visit, you will be given medication to take daily (either valacyclovir or acyclovir; you will receive both medications at some point during this study). There will be a total of 9 study visits and each visit will last approximately 30 minutes. We will ask that you complete a daily symptom diary and collected daily home swabs 4-times a day, everyday during the study. Each daily home swab will take less than 3 minutes to perform.

Screening Assessment

Patients will be assessed for their eligibility to enter the study at a screening visit. After signing informed consent they will undergo a medical history and the following information will be recorded in the Case Report Form (CRF):

  • Demographic Data: Date of birth, sex, marital status, education and race
  • Previous antiviral medication taken
  • History of sexually transmitted infections and sexual history.

Start of Study Visit (Day 0) and Day 14, 28, 42, 56, 70, 84, 98 and 105 Follow-Up Visits.

Eligible patients will return to clinic to be given study drug and a patient diary card on which to record concomitant medications, signs and symptoms, and adverse experiences. The investigator will instruct the patient on daily home viral sample collection, taking the study drug, and completing the diary card. The patient will be instructed to return to clinic in 2 weeks, +/- 2 days. Medication compliance will be assessed at each visit using pill counts.

Crossover Study Visit Prior To Washout Period (Day 49-55)

Participants will not be given study drug or placebo during the 7-day washout period.

Daily Home Viral Sample Collection

Participants will collect swabs from the genital mucosa four times per day and store the samples in PCR media with preprinted labels. Women will swab the cervicovaginal, vulvar and perianal areas, and men will swab the penile and perianal. Every two weeks, they will return the samples to the Virology Research Clinic when they present for additional study drug and assessment.

Final Study Visit (Day 105)

At the final study visit at Day 105 or for premature discontinuation, the investigator will perform the activities at the regular study visits, with the exception of the dispensation of study drug.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Genital Herpes
  • Drug: acyclovir
    800 mg orally three times daily for 7 weeks
  • Drug: valacyclovir
    500 mg orally once daily for 7 weeks
    Other Name: Valtrex
  • Active Comparator: 1
    Intervention: Drug: acyclovir
  • Active Comparator: 2
    Intervention: Drug: valacyclovir
Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet. 2012 Feb 18;379(9816):641-7. doi: 10.1016/S0140-6736(11)61750-9. Epub 2012 Jan 4. Erratum in: Lancet. 2012 Feb 18;379(9816):616.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
82
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 18 years or older;
  2. HSV-2 seropositive by Western Blot;
  3. not receiving any drugs with known anti-HSV-2 activity for study duration;
  4. history of primary genital herpes infection within past 6 months OR history of 4 or more HSV recurrences per year during the past year OR 4 or more recurrences per year prior to initiation of suppressive antiviral therapy;
  5. able to comply with the study protocol;
  6. women of child bearing potential who are sexually active with men must be using a medically accepted method of contraception as judged by the investigator;
  7. women of child-bearing potential must have a negative pregnancy test (urine) at screening visit;
  8. in general good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's medical history;
  9. planning to remain resident in the area of the study center for the duration of the study participation;
  10. HIV seronegative.

Exclusion Criteria:

  1. hypersensitivity to acyclovir or valacyclovir;
  2. pregnant women;
  3. HIV positive or other immunosuppressed state, including chronic steroid use. Intermittent nasal or topical steroids are acceptable
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00362297
30520-D - Phase 1
No
Christine Johnston, MD, MPH, University of Washington
University of Washington
Not Provided
Principal Investigator: Christine Johnston, MD University of Washington
University of Washington
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP